Obesity Clinical Trial
Official title:
Peer Support and Mobile Technology Targeting Cardiometabolic Risk Reduction in Young Adults With Serious Mental Illness
Verified date | October 2022 |
Source | Dartmouth-Hitchcock Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition supported by a wearable Activity Tracking device (BEAT) in achieving clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness (SMI).
Status | Completed |
Enrollment | 150 |
Est. completion date | May 31, 2022 |
Est. primary completion date | May 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Young adults ages 18 to 35 - Chart diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression - Overweight or obese defined as BMI =25 - Enrolled in treatment at the agency for at least 3 months prior to study recruitment - Have not started taking Clozapine or Olanzapine antipsychotic medications over the prior 2 months (dose changes are allowed) - Able and willing to give written informed consent to participate in the study or able to assent with guardian consent - Willingness to be randomized to either of the two conditions - Able and willing to attend the weekly 60-minute weight management session, participate in the weekly 1-hour physical activity sessions, and use the Facebook and mHealth (i.e., Fitbits and text messaging) components of the PeerFIT program Exclusion Criteria: - Medical contraindication to weight loss (e.g., cancer, stroke, liver failure) - Medical conditions (e.g., diabetes, angina) that do not receive medical clearance by a primary care provider - Major surgery planned or likely to occur within the next 6 months - Prior or planned bariatric surgery - Use of prescription weight loss medication within the past 6 months - 5% or greater weight loss in 3 months prior to baseline - Currently enrolled in another weight reduction program - Pregnant or planning a pregnancy, or breastfeeding during study period - Cognitive impairment sufficient to interfere with participant's ability to provide informed consent, complete study questionnaires, or participate in a group intervention as indicated by a Mini Mental Status Examination score <24 - Active substance use determined to be incompatible with participation in the intervention identified by screening questionnaire that assesses for excessive use according to intake limits by gender - Use of anabolic steroids with the drug taken at least "most days of the week for the previous month" - Planning to leave agency or move out of geographic area within 12 months - People who are non-English speakers or who have major visual or hearing impairment will be excluded given the need to read the program materials and interact with technology. |
Country | Name | City | State |
---|---|---|---|
United States | Greater Nashua Mental Health Center | Nashua | New Hampshire |
United States | Community Mental Health Affiliates | New Britain | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Dartmouth-Hitchcock Medical Center | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in weight | Participants' weight will be measured in pounds (lbs.) on a flat, even surface with the use of a high-quality, calibrated professional medical scale, with the participant wearing indoor clothing and no shoes. | Baseline, 6 months, and 12 months | |
Primary | Change in 6-minute walk test | After a baseline blood pressure has been obtained, participants are asked to walk a measured distance as far as they are able in 6 minutes. | Baseline, 6 months, and 12 months | |
Secondary | Change in weight loss self-efficacy assessed using the Weight Efficacy Lifestyle (WEL) questionnaire | The Weight Efficacy Lifestyle (WEL) questionnaire will be used to measure self-efficacy for weight loss. The WEL consists of 20 items designed to measure self-confidence to control weight by resisting overeating in certain tempting situations. The total score will be used in analyses. The items are scored on a 10-point Likert scale from 0 ("not confident") to 10 ("very confident") and total score calculated as the sum of individual item responses. | Baseline, 6 months, and 12 months | |
Secondary | Change in self-efficacy for exercise behaviors assessed using the Self-efficacy for Exercise Behaviors (SEB) scale | The Self-efficacy for Exercise Behaviors (SEB) scale will be used to measure participants' self-efficacy related to the ability to exercise despite barriers. The 12-item scale consists of common barriers that might affect participation in exercise (e.g., feeling depressed, socializing, stressful life changes, household chores). For each situation, participants use the scale from 1 ("I know I cannot") to 5 ("I know I can") to describe his or her confidence that they could exercise in the face of these barriers. | Baseline, 6 months, and 12 months | |
Secondary | Change in peer support for health behavior change assessed using the 24-item Social Provisions Scale (SPS) | Participants' level of perceived peer support will be measured with the 24-item Social Provisions Scale (SPS). The SPS assesses six types of support from social relationships (guidance, reliable alliance, reassurance of worth, attachment, social integration, and opportunity for nurturance) and the total score will be used in the analysis. The items are scored on a 4-point Likert scale from 1 ("strongly disagree) to 4 ("strongly agree") as it pertains to relationships with group members. Higher scores indicate greater perceived support from group relationships. | Baseline, 6 months, and 12 months | |
Secondary | Change in serum lipids | Lipids will be measured using the CardioChek PA Analyzer, a hand-held dual testing system that produces values for total cholesterol, LDL, HDL, and triglycerides using a multi-panel test strip and a single drop of blood acquired with a finger prick. | Baseline, 6 months, and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |